Schott E, Ebert M P, Trojan J
Med. Klinik m. S. Hepatologie und Gastroenterologie, CVK, Charité Universitätsmedizin Berlin, Germany.
Z Gastroenterol. 2012 Sep;50(9):1018-27. doi: 10.1055/s-0032-1312771. Epub 2012 Sep 10.
Sorafenib, a receptor tyrosine kinase-inhibitor with anti-proliferative and anti-angiogenic activity, is currently the only approved systemic treatment for patients with hepatocellular carcinoma. It inhibits downstream signaling of VEGFR-2, PDGFR, c-Kit receptors and BRAF. Over the last four years comprehensive experience with sorafenib in this indication has been accumulated. In this review we discuss the current data on the use of sorafenib in patients with advanced HCC including special patient populations such as patients with impaired liver function, patients after transplantation, and others. The most frequent side-effects and practical tips on how to manage them are discussed in detail. In addition, we summarize the current experimental data on the use of sorafenib in combination treatment, e. g., together with transarterial chemoembolisation or other targeted agents.
索拉非尼是一种具有抗增殖和抗血管生成活性的受体酪氨酸激酶抑制剂，目前是唯一被批准用于肝细胞癌患者的全身治疗药物。它可抑制血管内皮生长因子受体-2（VEGFR-2）、血小板衍生生长因子受体（PDGFR）、c-Kit受体和BRAF的下游信号传导。在过去四年中，已积累了索拉非尼用于该适应症的全面经验。在本综述中，我们讨论了索拉非尼用于晚期肝细胞癌患者的当前数据，包括特殊患者群体，如肝功能受损患者、移植后患者等。还详细讨论了最常见的副作用以及如何处理这些副作用的实用技巧。此外，我们总结了索拉非尼用于联合治疗（如与经动脉化疗栓塞或其他靶向药物联合）的当前实验数据。
